Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option : a cross-study comparison of the CANDOR and EQUULEUS studies
Leleu, Xavier (Service d'Hématologie et Thérapie cellulaire. CHU and Inserm)
Beksac, M. (Department of Hematology. Ankara University)
Chou, T. (Niigata Cancer Center Hospital)
Dimopoulos, Meletios (Hematology and Medical Oncology. Department of Clinical Therapeutics. National and Kapodistrian University of Athens School of Medicine)
Yoon, S. S. (Department of Internal Medicine. Seoul National University)
Prince, H. M. (Epworth Healthcare and Sir Peter MacCallum Department of Oncology. University of Melbourne)
Pour, L. (University Hospital Brno (República Txeca))
Shelekhova, T. (Clinic of Professional Pathology)
Chari, Ajai (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica). Tisch Cancer Institute)
Khurana, M. (Clinical Development. Oncology. Amgen Inc)
Zhang, J. (Global Biostatistical Science. Amgen Inc)
Obreja, M. (Global Biostatistical Science. Amgen Inc)
Qi, M. (Hematology and Oncology. Janssen Research and Development. LLC)
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Siegel, D. (John Theurer Cancer Center. Hackensack University Medical Center)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). We analyzed efficacy data from comparable CANDOR and EQUULEUS patients using inverse probability of treatment weighting (IPTW)-adjusted models. These weights were calculated from propensity scores derived to balance prespecified baseline covariates. The side-by-side and adjusted comparisons showed similar efficacy for overall response rates and progression-free survival in the two groups, with a series of sensitivity analyses showing consistent findings. Safety data were generally consistent with the known safety profiles of each individual drug. Once-weekly KdD70 is comparable to twice-weekly KdD56 in terms of efficacy and safety while being a more convenient dosing option.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Daratumumab ; Carfilzomib ; Multiple myeloma ; Weekly regimen
Publicat a:	Leukemia and Lymphoma, 2020 , ISSN 1029-2403

DOI: 10.1080/10428194.2020.1832672
PMID: 33112184

12 p, 1.8 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Institut de Recerca contra la Leucèmia Josep Carreras
Articles > Articles de recerca
Articles > Articles publicats